Tesamorelin

Mechanism of action

Agonism of the GHRH receptor (GHRHR) in the anterior pituitary → increased pulsatile secretion of GH → increased hepatic (and peripheral) production of IGF-1. Downstream effects: increased lipolysis and reduced visceral adipose tissue in some contexts; possible effects on glucose metabolism (potential worsening of glucose tolerance in predisposed individuals), fluid retention, and modulation of lipid markers. Because it acts through the GH/IGF-1 axis, it may influence proliferative processes and requires caution in the presence of neoplasms or at-risk conditions.

Supported benefits

• Reduction of visceral fat (VAT) in patients with HIV-associated lipodystrophy, measured by imaging (strong)
• Improvement in some body composition parameters (e.g., waist circumference, waist-to-hip ratio) in selected clinical populations (moderate)
• Increase in IGF-1 levels as a biomarker of GH axis activation (strong)
• Possible changes in lipid profile and cardiometabolic markers in specific contexts (results not consistent across studies) (limited)

Safety & side effects

• Injection site reactions (erythema, pain, itching, induration).
• Peripheral edema/fluid retention, arthralgia, myalgia (effects consistent with increased GH activity).
• Paresthesia or carpal tunnel–like symptoms (reported with GH axis activation in some individuals).
• Headache, nausea (less common).
• Increase in IGF-1 above physiological ranges in some cases (requires clinical monitoring).
• Possible worsening of glucose tolerance or increased blood glucose in predisposed individuals; significant risk in the presence of prediabetes/diabetes.

FAQ

Is it the same thing as growth hormone (GH)?

No. Tesamorelin is a GHRH analogue that stimulates the pituitary to release endogenous GH; GH is the hormone administered directly. Both increase activity of the GH/IGF-1 axis, but with different dynamics and response profiles.

Does it work for fat loss in general?

The strongest evidence concerns the reduction of visceral fat in a specific clinical population (HIV-associated lipodystrophy). There is no robust evidence for generalized use in healthy individuals or for non-selective weight loss.

What are the main metabolic risks?

A significant risk is impaired glucose tolerance (increased blood glucose or worsening glycemic control), in addition to fluid retention and possible neuromuscular symptoms. Increased IGF-1 requires caution in individuals with oncologic risk.

Are the effects permanent?

In several studies, some of the benefits on visceral fat reduction tended to diminish after discontinuation, suggesting that the effect is largely dependent on continued treatment and the clinical context.

Is it safe to buy it online as a “research peptide”?

Purchasing from unregulated channels carries high risks: unverifiable purity and dose, microbiological/endotoxin contamination, peptide degradation, and lack of quality control and pharmacovigilance.